Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Allows Claims on Regulus miRNA Patent Application

Premium

Regulus Therapeutics said this week that the US Patent and Trademark Office has allowed claims in a patent application, owned by Stanford University and exclusively licensed to Regulus, covering methods of antagonizing miR-181a to regulate immune response.

The microRNA has been "shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli, and modulation of miR-181a could lead to a novel treatment of inflammatory disease," the company said.

Specifically, "the newly allowed claims cover methods of modulating miR-181a in T cells, to raise the T cell receptor signaling threshold, and decrease the sensitivity of T cells to antigen stimulation," Regulus said. "The claims cover the use of a broad class of [miRNA antagonists against] miR-181a," including ones with varying lengths and chemical modifications.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.